Peginterferon alfa-2a biosimilar - Biogenomics

Drug Profile

Peginterferon alfa-2a biosimilar - Biogenomics

Alternative Names: Peginterferon alfa-2a biosimilar - Biogenomics; Peginterferon alpha-2a - Biogenomics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogenomics
  • Class Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Interferon alfa 2a stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-C in India (SC, Injection)
  • 15 Mar 2016 Biomarkers information updated
  • 16 Jan 2014 Peginterferon alfa-2a - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top